Menu Search
Equities

Kintor Pharmaceutical Ltd

9939:HKG.HS

Kintor Pharmaceutical Ltd

Actions
  • Price (HKD)1.21
  • Today's Change0.150 / 14.15%
  • Shares traded8.20m
  • 1 Year change-76.41%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China. The Company is focused on the research and development of drugs for cancers and other androgen receptor (AR) related diseases. Its primary drug candidate is Proxalutamide which is in phase III clinical trials in China for metastatic castration-resistant prostate cancer (mCRPC). The Company are also developing other drug candidates, including a phase II small molecule drug candidate Pyrilutamide, a phase II monoclonal antibody drug candidate ALK-1, a phase I mTOR inhibitor drug candidate Detorsertib and an inhibitor of the hedgehog signal translation pathway GT1708F.

  • Revenue in HKD (TTM)0.00
  • Net income in HKD-1.15bn
  • Incorporated2018
  • Employees225.00
  • Location
    Kintor Pharmaceutical LtdNo.20 Songbei RoadSuzhou Industrial ParkSUZHOU 215123ChinaCHN
  • Phone+86 51 262639909
  • Websitehttps://www.kintor.com.cn/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.